Montefiore Einstein Comprehensive Cancer Center | Strategic Alliance Partners

August 21, 2020

Edward Chu, MD, MMS, discusses the impact of the phase 3 MK-3475-177/KEYNOTE-177 trial in ​metastatic colorectal cancer.

August 19, 2020

Early in the pandemic, the Montefiore hospital leadership had the forethought and insight to create a reliable and robust outcomes data collection system on all patients with a diagnosis of COVID-19 being seen and treated within the system.

July 22, 2020

The prominent physician-scientist will also be appointed professor of medicine and molecular pharmacology at Einstein

April 22, 2020

Investigators at Montefiore showed that axicabtagene-ciloleucel can be used successfully in ethnically diverse patients with high-risk, relapsed/refractory diffuse large B-cell lymphoma at an inner-city hospital.

April 17, 2020

Balazs Halmos, MD, MS, provides insight on preventive measures put in place at his institution, day-to-day challenges faced in practice, and how he is staying connected with the broader community to share information.

April 15, 2020

Balazs Halmos, MD, MS, provides insight into how his institution continues to adapt in response to the COVID-19 crisis.

March 20, 2020

Balazs Halmos, MD, MA, discusses the advances that have been made in the treatment of patients with metastatic non–small cell lung cancer, ongoing biomarker research, and the importance of molecular testing.

March 17, 2020

Balazs Halmos, MD, discusses the implications of the emergence of osimertinib in the frontline treatment of patients with EGFR-mutated non–small cell lung cancer, the efforts being made to address resistance to the third-generation EGFR TKI, and the promise of circulating tumor DNA in the space.

January 21, 2020

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, professor of Medicine & Obstetrics, Gynecology, and Women’s Health at the Albert Einstein College of Medicine, and associate chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, discusses the utility of liquid biopsies in breast cancer.

November 27, 2019

Roman Perez-Soler, MD, discusses the utility of liquid biopsy in lung cancer.

November 23, 2019

Lakshmi N. Rajdev, MD, discusses the use of somatostatin analogs in patients with neuroendocrine tumors.

November 21, 2019

Andreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.

November 11, 2019

Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.

November 06, 2019

Lakshmi N. Rajdev, MD, an associate professor, Department of Medicine (Oncology), at Albert Einstein College of Medicine, Montefiore Medical Center, discusses the difference between cancers and carcinomas in neuroendocrine tumors (NETs).

November 02, 2019

Andreas Kaubisch, MD, discusses available treatment options for hepatocellular carcinoma.

October 31, 2019

Lakshmi N. Rajdev, MD, discusses classifying and grading neuroendocrine tumors (NETs), treating patients with NETs, and novel therapeutic strategies in the pipeline.

August 01, 2019

It is crucial to develop screening programs for stomach cancer in the United States in order to make diagnoses at earlier stages of disease, provide better care, and improve outcomes.

June 24, 2019

Ana Acuna-Villaorduna, MD, provides further insight into the study that compares age and race as factors for the incidence of early-onset colorectal cancer.

May 21, 2019

In an effort to build more sophisticated protocols that keep QoL and cost questions at the forefront, Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine’s Institute for Onco-Physics created a mathematical model to identify the optimal candidates for proton therapy, the most modern form of radiation therapy for patients with head and neck cancers.

April 01, 2019

Benjamin A. Gartrell, MD, assistant professor of urology, Albert Einstein College of Medicine, medical oncologist, Montefiore Medical Center, discusses the tolerability of SM-88 in the treatment of patients with prostate cancer.